Nanobiotix Closes $98.6M Global Offering, Including Full Over-Allotment Exercise
NBTX has more than doubled off its 52-week low of $3.64.
Summary
Nanobiotix announced the closing of its global offering, raising approximately $98.6 million, which included the full exercise of the underwriters' over-allotment option.
Key Events · Financing and Capital Events · NBTX
-
Global Offering Closed
Nanobiotix successfully closed its global offering on May 26, 2026, raising approximately $98.6 million. This finalizes the capital raise announced on May 21, 2026.
-
Over-Allotment Option Fully Exercised
The underwriters fully exercised their option to purchase an additional 33,805 American Depositary Shares (ADSs), demonstrating strong investor demand for the offering.
-
Offering Details and Pricing
The offering included 225,373 ADSs, 1,959,289 ordinary shares, and 345,099 pre-funded warrants. The ADSs were priced at $38.98 each, corresponding to €33.60 per ordinary share, representing a modest discount to the current market price.
-
Extended Cash Runway
The proceeds from this significant capital raise are intended to extend the company's cash runway, supporting ongoing clinical development and operational needs.
Analysis · NBTX · Life Sciences
Nanobiotix has successfully closed its global offering, raising approximately $98.6 million. This capital infusion is substantial for a life sciences company, providing critical funding to extend its cash runway and advance its clinical pipeline. The offering was oversubscribed, and the underwriters fully exercised their over-allotment option, indicating strong investor demand and confidence following recent positive clinical and regulatory updates. While dilutive, the successful execution of this capital raise at a modest discount to the current market price is a positive signal for the company's financial stability and ability to fund its strategic initiatives.
At the time of this filing, NBTX was trading at $40.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $3.64 to $57.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.